导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.21% | 1255/4773 |
| 近一周 | -2.45% | 2204/5462 |
| 近一月 | -4.59% | 2581/5421 |
| 近一季 | -7.95% | 2604/5209 |
| 近半年 | -5.12% | 2745/4920 |
| 近一年 | 10.12% | 1028/4366 |
| 近两年 | 77.21% | 849/2954 |
| 近三年 | 41.74% | 680/2253 |
| 成立以来 | 113.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.05% 1083/4961 |
18.96% 1335/5312 |
- - |
- - |
| 2025 | 32.20% 1194/4813 |
2.08% 1474/3635 |
1.96% 1983/4076 |
24.71% 1441/4524 |
1.85% 1191/4813 |
| 2024 | 8.01% 1598/3463 |
-2.72% 1416/2808 |
-5.12% 1654/3014 |
15.26% 1772/3129 |
1.53% 1056/3463 |
| 2023 | -6.35% 833/2656 |
7.23% 590/2280 |
-4.09% 1042/2385 |
-4.63% 1186/2515 |
-4.52% 1071/2655 |
| 2022 | -18.25% 680/2207 |
-13.31% 732/1919 |
2.64% 1277/2016 |
-10.39% 396/2113 |
2.54% 905/2208 |
| 2021 | 15.15% 311/1822 |
-1.63% 525/1255 |
8.95% 596/1330 |
4.16% 377/1466 |
3.14% 468/1822 |
| 2020 | 20.79% 705/1250 |
-4.15% 339/1028 |
15.53% 489/1067 |
6.30% 857/1164 |
2.62% 978/1184 |
| 2019 | 26.78% 567/1092 |
31.45% 202/754 |
-9.44% 654/804 |
0.34% 528/850 |
6.14% 652/918 |
| 2018 | -29.43% 451/834 |
- - |
- - |
- - |
-12.32% 435/691 |
| 2017 | -0.89% 486/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.18% 410/605 |
- - |
- - |
- - |
- - |
| 2015 | 25.39% 91/575 |
- - |
- - |
- - |
- - |
| 2014 | 33.36% 153/237 |
- - |
- - |
- - |
- - |
| 2013 | 14.71% 29/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 工银中证500ETF联接A VS. 长安沪深300非周期A(740101) |